Lifecore BiomedicalLFCR
LFCR
About: Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
Employees: 524
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
290% more call options, than puts
Call options by funds: $425K | Put options by funds: $109K
146% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 13
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
25% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 5 (+1) [Q3]
9% more funds holding
Funds holding: 74 [Q2] → 81 (+7) [Q3]
1.34% less ownership
Funds ownership: 69.1% [Q2] → 67.76% (-1.34%) [Q3]
5% less capital invested
Capital invested by funds: $123M [Q2] → $117M (-$6.24M) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
5%
downside
Avg. target
$8
27%
upside
High target
$10
58%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Stephens & Co. Jacob Johnson 58% 1-year accuracy 11 / 19 met price target | 5%downside $6 | Equal-Weight Reiterated | 3 Jan 2025 |
Craig-Hallum Matthew Hewitt 50% 1-year accuracy 1 / 2 met price target | 58%upside $10 | Buy Maintained | 22 Nov 2024 |
Financial journalist opinion
Based on 21 articles about LFCR published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Lifecore Biomedical Announces Special Stockholder Meeting
Company Seeking to Remove Convertible Preferred Stock Exchange Cap to Permit Potential Conversion of Series A Preferred Stock as Contemplated by the Series A Preferred Stock Terms Company Seeking to Remove Convertible Preferred Stock Exchange Cap to Permit Potential Conversion of Series A Preferred Stock as Contemplated by the Series A Preferred Stock Terms
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Neutral
Accesswire
2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Neutral
Accesswire
2 weeks ago
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Neutral
Accesswire
2 weeks ago
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Neutral
Accesswire
2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Neutral
Accesswire
2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Neutral
GlobeNewsWire
2 weeks ago
Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million
Company Believes it is Well Positioned for Mid-Term and Long-Term Growth as Current Capacity Continues to Support up to $300 Million in Annual Revenue
Neutral
GlobeNewsWire
2 weeks ago
Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference
CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 43rd Annual J.P. Morgan Healthcare Conference. The conference will take place January 13-16, 2025, in San Francisco, California.
Charts implemented using Lightweight Charts™